EGFR and non-small cell lung carcinoma: Osimertinib (AZD9291), the first third-generation oral potent and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), was approved by US-FDA and NMPA for first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with acquired metastatic EGFR T790M mutation [1, 2].